Mapping the availability of RSV vaccine uptake data across Europe: a scoping review
Abstract
Issue/Problem: Respiratory syncytial virus (RSV) is a leading cause of infant hospitalisation and morbidity across Europe, placing significant seasonal pressure on health services. New maternal and infant immunisation programmes have been implemented variably across countries. Programme effectiveness will depend on uptake of these strategies, and data are essential to enable evaluation, support shared learning, and ensure equitable access. We conducted a scoping review to map current RSV immunisation policies and the availability of uptake data across countries in Europe.
Description of the problem: We followed PRISMA-ScR guidelines and conducted a scoping review using PubMed, Google Scholar, and grey literature, including official government policy documents. Key search terms included “RSV”, “uptake”, “maternal vaccine”, “nirsevimab”, “coverage”, and “Europe”. Data were charted to address the following questions: (1) What immunisation strategy is used by each country as of April 2026 (maternal/infant/universal/at-risk)? (2) What is the availability of uptake data for these immunisation strategies? (3) At what level are these data reported (regional/national)?
Results: Data were identified for 32 countries in Europe. Immunisation policies reported at the start of the 2025/2026 RSV season remained unchanged in April 2026, with most countries funding universal infant immunisation programmes. Uptake data was available for 16 countries (50%). Among these, 3/16 (19%) reported both nirsevimab and maternal vaccine uptake, 5/16 (31%) maternal vaccination only, and 7/16 (44%) nirsevimab only. Most data derive from regional studies, hospital cohorts or short-term evaluations rather than routine national surveillance data.
Lesson: Currently, data availability on uptake of new RSV immunisation strategies is low, limiting comparison of coverage and equity between countries and enabling shared learning on RSV immunisation implementation.
Key messages: • RSV maternal and infant immunisation uptake data availability varies across European countries.
• Increasing availability of uptake data would facilitate shared learning as countries implement these new immunisation strategies.
Related
- Recombinant Zoster Vaccine Uptake in Patients with Noninfectious Ocular Inflammatory Diseases Receiving Immunosuppression
- HPV vaccine uptake and barriers among adolescent girls and young women living in the urban slums of Kampala, Uganda
- HPV Vaccination Uptake Among Vaccine-Eligible U.S. Adults with and Without a Cancer History: A National Health and Nutrition Examination Survey Analysis, 2011-2023.
- RSV vaccine uptake among Medicare Advantage enrollees: August 2023 to December 2024.
- Changing to a single-dose HPV vaccine schedule: impact on vaccine uptake and inequities in Ireland
BibTeX
@article{mehta2026mapping,
title = {{Mapping the availability of RSV vaccine uptake data across Europe: a scoping review}},
author = {S Mehta and K Foley and AM Hirvonen and M Celebrin and A Odone and H Skirrow},
journal = {The European Journal of Public Health},
year = {2026},
month = oct,
doi = {10.1093/eurpub/ckag169.300},
url = {https://doi.org/10.1093/eurpub/ckag169.300},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Mapping the availability of RSV vaccine uptake data across Europe: a scoping review
AU - S Mehta
AU - K Foley
AU - AM Hirvonen
AU - M Celebrin
AU - A Odone
AU - H Skirrow
PY - 2026
DA - 2026/10/01
JO - The European Journal of Public Health
DO - 10.1093/eurpub/ckag169.300
UR - https://doi.org/10.1093/eurpub/ckag169.300
AB - Issue/Problem: Respiratory syncytial virus (RSV) is a leading cause of infant hospitalisation and morbidity across Europe, placing significant seasonal pressure on health services. New maternal and infant immunisation programmes have been implemented variably across countries. Programme effectiveness will depend on uptake of these strategies, and data are essential to enable evaluation, support shared learning, and ensure equitable access. We conducted a scoping review to map current RSV immunisation policies and the availability of uptake data across countries in Europe. Description of the problem: We followed PRISMA-ScR guidelines and conducted a scoping review using PubMed, Google Scholar, and grey literature, including official government policy documents. Key search terms included “RSV”, “uptake”, “maternal vaccine”, “nirsevimab”, “coverage”, and “Europe”. Data were charted to address the following questions: (1) What immunisation strategy is used by each country as of April 2026 (maternal/infant/universal/at-risk)? (2) What is the availability of uptake data for these immunisation strategies? (3) At what level are these data reported (regional/national)? Results: Data were identified for 32 countries in Europe. Immunisation policies reported at the start of the 2025/2026 RSV season remained unchanged in April 2026, with most countries funding universal infant immunisation programmes. Uptake data was available for 16 countries (50%). Among these, 3/16 (19%) reported both nirsevimab and maternal vaccine uptake, 5/16 (31%) maternal vaccination only, and 7/16 (44%) nirsevimab only. Most data derive from regional studies, hospital cohorts or short-term evaluations rather than routine national surveillance data. Lesson: Currently, data availability on uptake of new RSV immunisation strategies is low, limiting comparison of coverage and equity between countries and enabling shared learning on RSV immunisation implementation. Key messages: • RSV maternal and infant immunisation uptake data availability varies across European countries. • Increasing availability of uptake data would facilitate shared learning as countries implement these new immunisation strategies.
SN - 1101-1262
SN - 1464-360X
ER -